Astex has used its fragment-based drug discovery platform to identify a new allosteric binding site on the full-length HCV NS3/4A protein and thinks compounds that bind the site can inhibit the protein's helicase activity in addition to its proteolytic activity. The result could be molecules with better efficacy than existing HCV drugs that target the protease active site.